Skip to main content
QCLS
NASDAQ Life Sciences

PharmaCyte Reaches 49.99% Stake in Q/C Technologies Through Warrant Exchange

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.28
Mkt Cap
$2.4M
52W Low
$0.275
52W High
$8.17
52W Position info
1.8% above low
Off High info
97% below high
Rel. Volume
Market data snapshot near publication time

QCLS is trading near its 52-week low of $0.275 (1.8% above the low).

Summary

PharmaCyte exchanged 851,304 Series G warrants for 4,982,272 Q/C Technologies shares at an implied $0.3101, reaching a 49.99% beneficial stake. Charters were amended to cap it there, and Series H maturity was pushed to September 2027.


Key Events · Ownership and Investor Activity · QCLS

  • Warrant Exchange Creates 49.99% Holder

    PharmaCyte exchanged 851,304 Series G Long-Term Warrants for 4,982,272 common shares, valuing the exchange at $0.3101 per share (Black-Scholes value divided by the prior closing price).

  • Ownership Math and Share Base

    Beneficial ownership totals 8,446,093 shares (5,152,000 held plus 3,294,093 acquirable within 60 days), or 49.99% of a base of 8,619,201 outstanding plus 4,982,272 exchange shares plus 3,294,093 acquirable shares.

  • Charter Caps and Maturity Extension

    The November 20 Omnibus Amendment adds a 49.99% beneficial ownership limitation to the Series G and Series H charters and Series G warrants, and extends Series H maturity from March 2, 2027 to September 2, 2027.

  • Context: Nasdaq Bid Deficiency

    Follows the November 13 8-K disclosing a November 6 Nasdaq notice that QCLS traded below $1.00 for 30 consecutive days; the stock is at $0.28.


Analysis · QCLS · Life Sciences

PharmaCyte converted 851,304 Series G Long-Term Warrants into 4,982,272 common shares at an implied $0.3101 per share, lifting its beneficial ownership to 8,446,093 shares — 49.99% of the class. That is a controlling-level stake in a company with a $2.4M market cap trading near its 52-week low, and it comes days after a Nasdaq $1.00 bid deficiency notice. The same-day Omnibus Amendment caps PharmaCyte at 49.99% and extends Series H maturity to September 2, 2027, so the overhang is now bounded but the concentration risk is real: one holder effectively controls the equity.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QCLS was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $0.28 to $8.17. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QCLS - Latest Insights

QCLS
Nov 20, 2026, 5:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.270
Real-time Price: $0.280 info
Change: +$0.010 (+4%) info
Market Cap: $2.4M info
QCLS
Nov 16, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3031
Real-time Price: $0.280 info
Change: -$0.0231 (-8%) info
Market Cap: $2.4M info
QCLS
Nov 13, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.3064
Real-time Price: $0.280 info
Change: -$0.0264 (-9%) info
Market Cap: $2.4M info
QCLS
Aug 12, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.89
Real-time Price: $0.280 info
Change: -$2.61 (-90%) info
Market Cap: $2.4M info
QCLS
Jul 02, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $3.92
Real-time Price: $0.280 info
Change: -$3.64 (-93%) info
Market Cap: $2.4M info